|
|
Article: Genentech's Avastin improves survival in metastatic colorectal cancer patients.
- Article from:
- Pharma Marketletter
- Article date:
- June 9, 2003
CopyrightCOPYRIGHT 2003 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
At the American Society of Clinical Oncology annual meeting in Chicago, USA, Genentech presented positive Phase III data for Avastin (bevacizumab) showing that the primary endpoint of the trial, an improvement in overall survival in previously-untreated metastatic colorectal cancer patients, was met. Subjects receiving Avastin and chemotherapy had a 50% increase in their chance of survival, compared to those on chemotherapy alone.
In the multicenter trial, 800 patients were randomized to receive either Avastin plus the standard-of-care chemotherapy (5-fluorouracil/leucovorin/irinotecan, called the Saltz regimen) or the Saltz regimen plus placebo. A third arm of ...